NASDAQ:AMDA - Amedica Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$0.51 -0.02 (-3.77 %)
(As of 07/16/2018 04:00 PM ET)
Previous Close$0.53
Today's Range$0.51 - $0.57
52-Week Range$0.50 - $6.96
Volume592,500 shs
Average Volume619,083 shs
Market Capitalization$2.36 million
P/E RatioN/A
Dividend YieldN/A
Amedica logoAmedica Corporation, a biomaterial company, develops, manufactures, and commercializes a range of medical devices based on its silicon nitride technology platform in the United States, Europe, and South America. The company offers silicon nitride implants to surgeons and hospitals for use in cervical and thoracolumbar spine surgery under the Valeo brand. It also provides a line of non-silicon nitride spinal fixation products to address spinal deformity and degenerative conditions. The company markets and sells its products directly; and through a network of independent sales distributors, as well original equipment manufacturer and private label partnerships. Amedica Corporation was founded in 1996 and is headquartered in Salt Lake City, Utah.

Receive AMDA News and Ratings via Email

Sign-up to receive the latest news and ratings for AMDA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Surgical & medical instruments


Debt-to-Equity RatioN/A
Current Ratio0.45
Quick Ratio0.30


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$11.22 million
Price / Sales0.20
Cash FlowN/A
Price / CashN/A
Book Value$1.80 per share
Price / Book0.28


EPS (Most Recent Fiscal Year)N/A
Net Income$-9,320,000.00
Net Margins-118.97%
Return on Equity-137.30%
Return on Assets-64.44%


Outstanding Shares4,420,000
Market Cap$2.36

The Truth About Cryptocurrencies

Amedica (NASDAQ:AMDA) Frequently Asked Questions

What is Amedica's stock symbol?

Amedica trades on the NASDAQ under the ticker symbol "AMDA."

When did Amedica's stock split? How did Amedica's stock split work?

Shares of Amedica reverse split on Friday, November 10th 2017. The 1-12 reverse split was announced on Friday, November 10th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, November 9th 2017. An investor that had 100 shares of Amedica stock prior to the reverse split would have 8 shares after the split.

How were Amedica's earnings last quarter?

Amedica Co. (NASDAQ:AMDA) issued its earnings results on Tuesday, November, 21st. The medical equipment provider reported ($0.93) EPS for the quarter, topping analysts' consensus estimates of ($0.94) by $0.01. The medical equipment provider earned $2.96 million during the quarter. Amedica had a negative net margin of 118.97% and a negative return on equity of 137.30%. View Amedica's Earnings History.

When is Amedica's next earnings date?

Amedica is scheduled to release their next quarterly earnings announcement on Tuesday, August, 21st 2018. View Earnings Estimates for Amedica.

What is the consensus analysts' recommendation for Amedica?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amedica in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold."

Are investors shorting Amedica?

Amedica saw a drop in short interest during the month of May. As of May 31st, there was short interest totalling 466,048 shares, a drop of 40.1% from the May 15th total of 777,657 shares. Based on an average trading volume of 566,967 shares, the days-to-cover ratio is presently 0.8 days. Currently, 10.9% of the company's stock are short sold. View Amedica's Current Options Chain.

Who are some of Amedica's key competitors?

Who are Amedica's key executives?

Amedica's management team includes the folowing people:
  • Dr. B. Sonny Bal, Chairman, CEO, Pres & Principal Financial Officer (Age 56)
  • Mr. Bryan J. McEntire, Chief Technology Officer (Age 66)
  • Mr. David O'brien, GM & VP Operations
  • Mr. Dana Lyons, VP of Sales & Marketing

Has Amedica been receiving favorable news coverage?

News headlines about AMDA stock have trended somewhat positive on Monday, according to Accern. The research group identifies negative and positive press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Amedica earned a daily sentiment score of 0.15 on Accern's scale. They also assigned media headlines about the medical equipment provider an impact score of 46.05 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next few days.

How do I buy shares of Amedica?

Shares of AMDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Amedica's stock price today?

One share of AMDA stock can currently be purchased for approximately $0.51.

How big of a company is Amedica?

Amedica has a market capitalization of $2.36 million and generates $11.22 million in revenue each year. Amedica employs 33 workers across the globe.

How can I contact Amedica?

Amedica's mailing address is 1885 WEST 2100 SOUTH, SALT LAKE CITY UT, 84119. The medical equipment provider can be reached via phone at 801-839-3500 or via email at [email protected]

MarketBeat Community Rating for Amedica (NASDAQ AMDA)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  155 (Vote Outperform)
Underperform Votes:  102 (Vote Underperform)
Total Votes:  257
MarketBeat's community ratings are surveys of what our community members think about Amedica and other stocks. Vote "Outperform" if you believe AMDA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMDA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/16/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.